The Top 5 Biosimilar Articles for the Week of July 1

Number 5: The FDA has approved Samsung Bioepis’ Pyzchiva (ustekinumab-ttwe) for the treatment of inflammatory conditions, including plaque psoriasis and ulcerative colitis.

Number 4: Two phase 3 trials, 1 in Crohn disease (CD), and 1 in ulcerative colitis (UC), found higher clinical remission rates in patients treated with the subcutaneous formulation of infliximab biosimilar CT-P13 (Remsima, Inflectra; Celltrion) compared with placebo as maintenance therapy following an induction phase of intravenous CT-P13.

Number 3: Key findings showed that there continues to be a lack of understanding and/or confidence in biosimilars among providers and patients, leading to diminished provider willingness to prescribe biosimilars and patient perceptions about the safety of switching to a biosimilar.

Number 2: Sarfaraz K. Niazi, PhD, champions the FDA's updated guidance to remove switching study data for companies seeking to obtain an interchangeability designation for their biosimilars.

Number 1: The FDA has approved Ahzantive (aflibercept-mrbb) as the third biosimilar referencing Eylea (aflibercept) for the treatment of eye conditions, including age-related macular degeneration.

To read all of these articles and more, visit centerforbiosimilars.com.